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Abstract
Background: Thrombotic processes play an essential role in the progression of the atheroma-
tosis and pathogenesis of acute coronary syndromes. The role of haemostatic factors in the
development of circulatory system diseases, ischaemic heart disease in particular, has met with
great research interest. The purpose of the present research is to define the role of haemostatic
factors in the pathogenesis of atheromatosis and ischaemic heart disease and also to deal with
their impact on diagnosis and prognosis. The aim of the present study was to evaluate thrombin
generation in vivo and to define the role of the main inhibitor of coagulation in patients with
acute myocardial infarction.
Methods: The study was performed using a group of 70 patients with acute myocardial
infarction with ST segment elevation (STEMI). The control group comprised 25 healthy
subjects matched for age and gender. Concentrations of thrombin-antithrombin III complexes
(TAT complexes) and antithrombin III (AT III) activity were measured; the sample was taken
before essential treatment was administered.
Results: In a group of patients with myocardial infarction, significantly higher average
concentrations of TAT complexes (p < 0.0001) and AT III activity (p < 0.001) were found. An
inverse correlation between AT III activity and kinase phosphocreatine concentration (p < 0.02)
was shown as well as a positive correlation between AT III activity and the time elapsing from
the onset of infarction symptoms to admission (p < 0.05). The increase in TAT complex
concentration and AT III activity did not depend on sex, age and risk factors for ischaemic
heart disease, nor did it predict late complications.
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Conclusions: The results provide evidence of an intensification of thrombinogenesis processes
in patients with acute myocardial infarction. The increase of AT III activity may reflect a compen-
satory mechanism of the haemostatic system with regard to intensified thrombinogenesis.
(Folia Cardiol. 2006; 13: 465–472)
Key words: myocardial infarction, antithrombin III (AT III), thrombin–
–antithrombin III complexes (TAT complexes)
Introduction
The formation of a thrombus in coronary ves-
sels is the most common cause of acute coronary syn-
dromes. The role of the haemostatic system in the
pathogenesis of ischaemic heart disease, acute cor-
onary syndromes in particular, has been the focus of
great research interest. In the diagnostics of intra-
vascular activation of coagulation tests can be applied
to monitor thrombus formation and its effects.
The strongest natural anticoagulant is anti-
thrombin III (AT III), a single-chain glicoprotein
consisting of 432 amino acids. This is produced in
the liver, in the endothelial cells, and probably in
the megacariocytes. In laboratory conditions it is
possible to evaluate either AT III concentration or
AT III activity, an evaluation that is much needed
for clinical purposes. AT III inactivates thrombin,
forming a stable and inactive thrombin-antithrombin
(TAT) complex. The endogenous co-factor, which
accelerates the reaction through a change in the
spatial structure of AT III, is heparan sulphate.
TAT complexes are amongst the most sensi-
tive and specific markers of thrombosis; an increase
in their concentration reflects the intensity of
thrombinogenesis in vivo [1–3]. Together with AT III,
the haemostatic factors which are natural coagu-
lants are less known with regard to their role in the
development of diseases of the cardiovascular sys-
tem. The relation between the risk and intensity of
coronary disease symptoms and AT III activity has
been shown in a small number of studies, but the
results remain ambiguous. At first it was thought
that only decreased values in the concentration or
activity of AT III were of importance and predis-
posed to acute thrombotic events. However, sub-
sequent reports showed the relationship between
a rise in the activity of AT III and an increased risk
of intravascular clotting, particularly when coexist-
ing with hyperfibrinogenaemia or increased throm-
boplastic activity [4, 5].
The purpose of the study was to evaluate
thrombinogenesis intensity in vivo by assessment
of TAT complex concentration and to define the role
of the main coagulation inhibitor, AT III, in patients
at an early stage of acute myocardial infarction be-
fore the administration of the relevant treatment
which, it is assumed, modifies the haemostatic pa-
rameters.
Method
The study comprised 70 patients (54 men and
16 women with an average age of 54.1 ± 8.7 years)
with acute myocardial infarction with ST segment
elevation (STEMI). Myocardial infarction was diag-
nosed by anamnesis, ECG findings and laboratory
results which confirmed necrosis of the myocardial
cells: troponin I, kinase phosphocreatine (CPK) and
its CK-MB fraction). In the group examined the
mean time elapsing between the onset of chest pain
and hospitalisation was 6 hours.
The exclusion criteria were as follows: age
above 70, resuscitation on admission to hospital,
cardiogenic shock at admission, pharmacologically
treated hyperlipidaemia, diabetes, neoplastic dis-
ease, other chronic disease (renal or hepatic insuf-
ficiency) and oral anticoagulant therapy. The con-
trol group comprised 25 healthy subjects selected
by age and sex.
TAT complex concentrations and AT III activ-
ity were measured in all the patients under exami-
nation and in the subjects of the control group. TAT
complex concentrations were measured by means
of a commercial ELISA method kit (an Enzygnost
TAT kit by Behring-Marburg, standard: 1.0–4.1 mg/L).
The plasma activity of AT III was measured using
chromogenic substrate and spectrophotometry (the
Berichrom Antithrombin III test by Behringer Man-
nheim with a normal value range of 80–120%).
Blood for the above-mentioned tests was taken,
together with the blood sample for other routine
diagnostic measurements, directly after admission
to hospital, after the informed consent of the pa-
tients had been obtained and before administration
of the relevant treatment.
All the results were analysed statistically. For
various samples basic statistics were calculated
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(mean value: x, standard deviation: SD). Addition-
ally, in view of the clear asymmetry in some sam-
ples, the values of the median, lower and upper
quartiles were calculated. The significance level
was set at p £ 0.05. Where all the values had a nor-
mal distribution, the standard Student’s t-test was
applied to compare the groups. However, when
a given value was not derived from a population with
normal distribution, the Mann-Whitney test (the
rank sum test) was used to compare two samples.
To investigate the relationships between individu-
al features a correlation matrix was defined and the
Pearson correlation coefficient calculated. In the
case of a pair of non-parametric values, the Spear-
man rank correlation coefficient was computed. The
results were worked out using Microsoft® Access
2.0 for Windows and StatSoft® Statistica 5.0 for
Windows.
Informed consent was obtained from each pa-
tient. The protocol for the study was approved by
the Local Ethics Committee.
Results
The results obtained in the group of patients with
myocardial infarction (n = 70) were compared to the
results for the healthy subjects who had formed a con-
trol group (n = 25). The groups did not differ statisti-
cally with respect to age, sex, weight and height (BMI)
or other basic biochemical parameters (Table 1).
Significant discrepancies in additional tests re-
sulted from the definition of the group investigated
and concerned parameters directly linked to myocar-
dial infarction (risk factors of myocardial ischaemia
and biochemical markers of myocardial infarction).
In the group of patients studied with myocar-
dial infarction the TAT complex concentration
was increased in comparison with standard val-
ues and significantly higher than in the control
group (p < 0.0001). The mean activity of AT III
in the group of patients with myocardial infarc-
tion was significantly higher compared to the con-
trol group (p < 0.002) (Table 2).
Table 1. General characteristic and essential laboratory parameters in the group with myocardial inf-
arction and the control group.
Myocardial infarction Control group p
Age (years) 54.1 ± 7.7 50.8± 7.2 NS
Body mass index 26.7 ± 3.5 27.6± 4.3 NS
Hb [g/dl] 14.5 ± 1.1 15.0± 1.0 NS
Ht (%) 44 ± 3.8 44± 2.7 NS
Creatinine [mg/dl] 0.91 ± 0.19 0.89± 0.13 NS
BUN [mg/dl] 15.3 ± 4.7 14.6± 3.8 NS
SGPT [U/L] 35.5 ± 19.7 28.6± 17.5 NS
Glucose [mg/dl] 123 ± 32 105± 18 0.02
Total cholesterol [mg/dl] 238 ± 46 209± 43 0.01
LDL cholesterol [mg/dl] 159 ± 40 137± 36 0.05
HDL cholesterol [mg/dl] 49 ± 14 52± 11 NS
Triglycerides [mg/dl] 159 ± 105 107± 46 0.01
CPK [U/L] 1681 ± 1630 118± 47 0.0001
CK-MB [U/L] 212 ± 374 11± 5 0.0001
Table 2. The comparison between TAT complex concentration and AT III activity in patients with myo-
cardial infarction and in the control group.
Myocardial infarction Control group p
X ± SD Mediana Lower Upper X ± SD Mediana Lower Upper
quartile  quartile quartile  quartile
TAT [µg/L] 26.3 ± 36.7 6.8 3.9 33.9 2.9 ± 1.2 2.9 1.9 3.7 0.0001
AT III (%) 115.5 ± 17.2 116.1 103.4 126.0 102.5 ± 13.7 100.1 95.3 110.2 0.001
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Additionally, an inverse correlation was shown
between AT III activity and maximal CPK concen-
tration in the patients studied (correlation coefficient
r = –0.27 and level of relevance p < 0.02) (Fig. 1).
A positive correlation was found (r = 0.24,
p < 0.05) between the activity of AT III and the time
elapsing between the onset of infarction symptoms
and hospital admission, the so called “pre-hospital
period” (Fig. 2).
No significant differences between the sexes
were found in TAT complex concentration and AT III
activity.
Selected parameters of haemostasis were also
compared between the age groups (£ 55 years vs.
> 55 years). In the subgroup of older patients the
mean values of TAT complex concentration were
higher albeit statistically insignificant. No substan-
tial differences were found in TAT complex concen-
tration and AT III activity in patients with early
diagnosis of coronary disease or patients with
myocardial infarction as the first symptom of ischae-
mic heart disease.
To analyse the role of obesity with reference
to the examined parameters of homeostasis, the
group of patients with BMI above 30 was selected.
No significant differences in TAT complex concen-
trations or AT III activity were found in these
patients as compared to other patients (BMI £ 30),
although the mean concentration of TAT complex-
es was lower and AT III activity higher in the group
with BMI > 30.
Concentrations of TAT complexes and AT III
activity were evaluated in the group of patients with
complications in the course of myocardial infarction
(recurrent infarction during hospitalisation or death)
and those without complications. No significant dif-
ferences in the studied parameters were found in
either group of patients. No relationship was dem-
onstrated between TAT complex concentration and
AT III activity and the values of total cholesterol,
LDL-cholesterol, HDL-cholesterol or triglycerides.
No substantial differences were found in TAT com-
plex concentration and AT III activity in relation to
previous smoking or a history of hypertension.
Discussion
The study evaluated selected parameters of
coagulation in acute myocardial infarction deter-
mined as soon as possible after the onset of symp-
toms. The method applied allowed the impact of
pharmacological treatment on the parameters of
haemostasis in acute myocardial infarction to be
excluded. Similarly, the material was selected so
that all factors which could distort the results, other
than myocardial infarction itself, were marginalised.
Thrombin-antithrombin complexes
A clear rise in TAT complexes within the first
24 hours of infarction appeared to be consistent with
the results of several studies and reports and showed
distinct activation of the coagulation system cascade
during acute myocardial infarction [6–9].
In the TIMI-5 study (Thrombolysis in Myocar-
dial Infarction) the baseline values of TAT complex
concentration estimated before the onset of rele-
vant therapy were higher alongside higher concen-
trations of fibrinogen A and prothrombin fragments
F1+2 [10]. The results of Lopez et al. [11] showed
a significant increase in TAT complex concentration
in acute myocardial infarction as compared to the
control group (p < 0.0001). Furthermore, a signif-
icant rise was found in prothrombin fragments
F1+2, fibrinopeptide A, PAP complexes and D-dimers,
Figure 1. The correlation between AT III activity and ma-
ximum CPK levels in patients with myocardial infarction.
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Figure 2. The correlation between AT III activity and the
duration of the pre-hospital period in patients with myo-
cardial infarction.
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as well as positive correlations between: TAT com-
plex concentration and D-dimers, TAT complexes
and PAP, PAP complexes and D-dimers. This would
appear to support both coagulation and fibrinolysis
activation in the acute phase of the disease. Szczek-
lik et al. observed significantly higher values of TAT
complexes in a group of 100 patients with acute myo-
cardial infarction as compared to the control group
(35.7 ± 4.7 mg/L vs. 2.1 ± 0.8 mg/L) [12].
An attempt was made by Italian investigators
to define the time relations between ischaemic
events and activation of the coagulation system in
unstable angina pectoris [13]. The results demon-
strated a higher production of thrombin in unstable
angina pectoris; nevertheless, they also showed
that such activation was not always related time-
wise to the clinical manifestation of angina. No ac-
tivation of the coagulation system was found in
about 25% of ischaemic events, and more than half
of all periods of intensified coagulation did not re-
sult in clinical symptoms of ischaemia. According
to the authors [13], such results are not surprising
and can be explained by the short half-life of the
TAT complex in serum or by the role of vascular
contraction in the pathogenesis of coronary events.
The possible coexistence of an increased production
of thrombin outside the coronary vessels may explain
the false positive results. The results obtained dem-
onstrate that coronary instability results from nu-
merous processes. A certain “critical mass” of local
thrombus may be necessary for increased TAT lev-
els to be found in the peripheral circulation [14, 15].
In our research material a concentration of
TAT complexes above the upper limit was found in
47 (71%) of cases. An analogous index given by
Seitz et al. [14] accounted for 50% of cases, while
in the group of patients with myocardial infarction
reported by Szczeklik et al. [12] the percentage of
“positive” results was highest and reached 90%.
We found no significant differences in TAT
complex concentration between men and women.
The comparison of age groups (those below and
those above 55 years) showed higher mean values
of the parameter in older patients (6.2 mg/L vs.
7.7 mg/L) but these differences were statistically in-
significant.
The results are consistent with the Giansante
report, which did not find any relation between TAT
complex concentration and age, while the concen-
tration in women was significantly higher (p < 0.05)
compared to that in men in the groups studied [23].
In the material of Musiał et al. [16] mean concen-
trations of the TAT complexes in patients with cor-
onary disease were higher in women than in men.
These authors also showed a positive correlation
of TAT complexes in relation to age in women,
while no such relationship was found in the male
group. The absence of differences in concentration
of TAT complexes between women and men in our
research material could result from the relatively
small number of women (16 patients or 23% of the
group as a whole). The population of the study men-
tioned above comprised 417 patients, including
222 women (53%). Presumably sex-dependant dif-
ferences found in a stable clinical phase may become
blurred or may alter during intensified thrombino-
genesis as a result of an individual rise in marker
concentration.
No correlation was found in our material be-
tween the baseline concentration of TAT complex-
es and late complications of infarction during hos-
pitalisation. The values for TAT complexes deter-
mined by Szczeklik before the start of a relevant
treatment in patients did not enable infarction com-
plications to be predicted, while the dynamics of the
parameter showed a later distinct rise accompany-
ing complications (heart failure, recurrent infarc-
tion, death) [12, 17]. In the TIMI-5 study increased
mortality was associated with an increased concen-
tration of TAT complexes determined one hour af-
ter admission [10].
To sum up, in patients with acute myocardial
infarction a highly significant rise in TAT complex-
es was found, which was unrelated to any of the
factors analysed and which is in congruence with
reports by other authors. The rise in TAT complex-
es accompanying complications of infarction found
in some reports and in our research material was
observed at the moment of occurrence, while pre-
vious values were of no prognostic importance [12].
Antithrombin III
With regard to AT III, it is known that a defi-
ciency of coagulation inhibitors, including AT III,
increases the risk of venous thrombosis. Howev-
er, the results of studies on the relationships be-
tween this protein and arterial thrombosis are am-
biguous. The increased activity of AT III in acute
myocardial infarction found in the group of patients
studied is confirmed by reports by other authors.
However, any attempt to interpret the results re-
quires analysis of AT III values in healthy subjects
and in various clinical phases of ischaemic heart
disease.
The first significant study of the role of the
coagulation system in ischaemic heart disease was
a prospective Northwick Park Heart Study (NPHS),
in which 1511 subjects without ischaemic heart
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disease were enrolled [18]. Later the summary of
baseline results of the NPHS study was extended
by the observation of the group in question until the
end of 1990 as performed by Meade et al. [19]. This
showed that the highest number of deaths result-
ing from cardiovascular diseases (and ischaemic
heart disease) occurred in subjects in whom previ-
ous determinations of antithrombin were in the
marginal range (at the lower or upper limit). These
observations allowed the researchers to conclude
that a risk of death resulting from cardiovascular
system diseases was related to either low or high
values of AT III activity.
The ARIC and PLAT studies ascertained that
low values of AT III activity were related to an in-
creased risk of thrombosis and ischaemic events
[20, 21]. Among patients who participated in the
ECAT Study the AT III antigen level was lower
(p = 0.008) in patients after myocardial infarction
compared to other patients [22, 23].
In another significant population study, the
Rotterdam Study (n = 7983), AT III activity and the
degree of atheromatosis intensity were analysed.
The activity of AT III in men was highest in the
group of patients with moderate atheromatosis.
A greater intensity of atheromatosis was not asso-
ciated with a rise in the parameter in question but
rather with a decrease to the levels found in
a healthy population [5]. The combined results of
the NPHS, PLAT and Rotterdam Study allow re-
searchers to assume that in patients with an active
atheromatic process an increased level of AT III
activity can result from activation of a defensive
mechanism against a pro-thrombotic impact. The
efficiency of defensive mechanisms is limited and
we do not observe a further rise in antithrombin
activity in cases of advanced atheromatosis. In sub-
clinical thrombotic processes increased consump-
tion of AT III results in lower levels of this antico-
agulant, despite its increased production. As a re-
sult, either a rise or a drop in AT III activity can
signal vessel damage and an increased risk [5]. The
results of the Rotterdam Study showed that the
increased risk of cardiovascular diseases was relat-
ed to increased AT activity, whereas a drop in AT
activity, accompanying thrombotic vascular events,
reflected intensified consumption of AT.
The TIMI II (Thrombolysis in Myocardial Inf-
arction Phase II Trial) study was designed to veri-
fy the hypothesis that myocardial infarction was
related to the deficiency of coagulation inhibitors
AT III and proteins C and S. However, it appeared
that only the level of protein S was decreased, while
protein C and AT III were significantly higher in
patients with myocardial infarction as compared to
the control group [24]. These observations are con-
gruent with the results of the present study; in the
acute phase of myocardial infarction, significantly
higher values of AT III activity were found.
A deficiency of coagulation inhibitors, particu-
larly of AT III, both congenital and acquired, can
cause thrombophilia. In prospective observations of
a vast material a relationship was found between low
AT III activity and a higher risk of ischaemic heart
disease or exacerbation of existing disease [5, 19,
20, 25]. The explanation of the increased risk in
patients with higher AT III activity, found also in
NPHS, ARIC and Rotterdam Study, was more diffi-
cult to explain. It could be caused by a compensa-
tory reaction related to the intensity of the throm-
botic processes in the arteries with atheromatic
lesions [19, 26]. It seems that the higher activity of
AT III found in our study and in other reports [19, 24]
is a response to intensified thrombinogenesis and
increased consumption of antithrombin in acute
myocardial infarction.
In the our own research material no relation-
ship was found in patients with acute myocardial
infarction between AT III and sex, age, BMI, lip-
ids, history of hypertension and smoking. In the
reports evaluating the activity of AT III in patients
with exacerbation of ischaemic heart disease or
myocardial infarction no relationships were found
between this parameter and particular factors dif-
ferentiating the group evaluated [24, 27].
In the group of patients examined a negative
correlation was demonstrated between AT III ac-
tivity and a maximal concentration of CPK and
a positive correlation between AT III activity and
the time measured between the onset of infarction
symptoms to admission to hospital. The authors did
not find any reports in the literature which put for-
ward these relationships. We can justify the corre-
lations observed by assuming that the increased
activity of AT III demonstrated results from a de-
fensive reaction compensating for activation of the
coagulation processes. The longer pre-hospital pe-
riod corresponds to an increased activity of AT III;
this may support the idea of the gradual activation
of compensative mechanisms, the effect of which
increases with time. One may try to explain the
negative correlation of AT III and the maximal con-
centration of CPK as follows: the more intensified
reaction, which compensates for activation of coag-
ulation (higher AT III activity), is related to a low-
er level of the marker of myocardial cell lesion.
In the relationship discussed between AT III
and ischaemic heart disease two qualitatively
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different scenarios are possible. On the one hand,
decreased levels of AT III found in a stable clinical
period of coronary artery disease are the cause of
an increased thrombotic threat and predispose to
thrombotic events. This is supported by Thomp-
son’s et al. study [28], which shows a low level of
activity of AT III without simultaneous activation
of coagulation, which can be detrimental in ischae-
mic heart disease. On the other hand, an increased
level of activity of AT III can result from overcoag-
ulation, because activation of coagulation is a stim-
ulus which triggers compensative mechanisms,
manifesting themselves in the mobilisation of the
main coagulation inhibitor, namely an increase in
AT III activity [24].
Conclusions
1. In the group of patients examined with acute
myocardial infarction, higher concentrations of
TAT complexes are found in comparison with
healthy subjects in the control group.
2. Higher concentrations of TAT complexes pro-
vide evidence of the intensity of thrombinogen-
esis in patients with acute myocardial infarc-
tion, while the higher level of activity of AT III
could express the compensative mechanism of
thrombinogenesis.
3. Increased concentrations of TAT complexes
and AT III activity seem to be unrelated to pa-
tient age and sex or the presence and intensi-
ty of risk factors of ischaemic heart disease.
4. Higher concentrations of TAT complexes and
AT III activity probably have no prognostic im-
portance for the observed complications of myo-
cardial infarction.
5. The negative correlation between AT III and
maximal concentrations of CPK can point to
a possible protective role of this anticoagulant
in the process of the cardiomyocyte lesion dur-
ing acute myocardial infarction.
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